PALISEUL PHARMA
ActiveSummary
PALISEUL PHARMA has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €832k and a net result of €180k. Equity is growing by ~21.7% per year across the filed fiscal years. Its solvency ranks better than 47% of 6537 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.7% (low).
Checked score
Score 2024
69
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability77▼-12
Solvency55▼-29
Growth78=
Track record100
Bankruptcy probability, 12 months
0.7%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €55k at 30 days acceptable
Liquidity tight (current ratio 1.45 against 1.87 in 2023; short-term debt: 23.2% and cash: 16.2% of total assets), and 69.8% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 23-06-2025, 38 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
38 d early
2023
27 d early
2022
5 d early
2021
16 d early
2020
22 d early
2019
15 d early
← before the deadline
after the deadline →
Checked, nothing found (1)
Financials · fiscal year 2024, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€180k▼ 5.2%
2023 · €190k
2018: €155k
2019: €120k
2020: €152k
2021: €150k
2022: €169k
2023: €190k
2018 → 2024
Working capital
€286k▲ 2.5%
2023 · €279k
2018: €138k
2019: €185k
2020: €200k
2021: €204k
2022: €175k
2023: €279k
2018 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Equity€438k-€458k▲ 4.5%€562k▲ 22.8%€692k▲ 23.1%€832k▲ 20.3%
Operating result€190k-€192k▲ 1.0%€218k▲ 13.4%€240k▲ 9.8%€217k▼ 9.5%
Net result€152k-€150k▼ 1.6%€169k▲ 13.1%€190k▲ 12.1%€180k▼ 5.2%
Result per fiscal year
Operating resultNet result
The operating result falls in 2024; 2024 is 10% below 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €2.76M
Fixed assets
€1.83M ▲ 217%
Current assets
€926k ▲ 54.3%
Equity and liabilities €2.76M
Equity
€832k ▲ 20.3%
Debt
€1.93M ▲ 297%
Debt's share of the balance-sheet total rises from 41.2% to 69.8%. Equity and debt are higher.
Key figures and ratios
EBITDA
€259k▲
2023 · €256k
Cash flow
€223k▲
2023 · €206k
Current ratio
1.45▼
2023 · 1.87
Quick ratio
0.99▼
2023 · 1.24
Debt to equity
2.32▲
2023 · 0.70
ROE
21.6%▼
2023 · 27.4%
ROA
6.5%▼
2023 · 16.1%
Interest coverage
14.86▼
2023 · 58.48
Debt ≤ 1 year
€639k▲
2023 · €320k
Debt > 1 year
€1.28M▲
2023 · €165k
Income taxes
€22k▼
2023 · €45k
Staff costs
€211k▲
2023 · €167k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2024 against 2023 · 56 lines
Balance sheet
Code20232024
Assets
Total assets20/58€1.18M€2.76M▲
Fixed assets21/28€578k€1.83M▲
Intangible fixed assets21-€358k
Tangible fixed assets22/27€258k€1.22M▲
Land and buildings22€200k€189k▼
Plant, machinery and equipment23€32k€879k▲
Furniture and vehicles24€754€149k▲
Assets under construction and advance payments27€25k-
Financial fixed assets28€320k€258k▼
Current assets29/58€600k€926k▲
Stocks and contracts in progress3€202k€295k▲
Stocks30/36€202k€295k▲
Amounts receivable within one year40/41€121k€177k▲
Trade receivables40€110k€150k▲
Other amounts receivable41€11k€28k▲
Cash at bank and in hand54/58€272k€448k▲
Deferred charges and accrued income490/1€5k€5k▲
Equity and liabilities
Total equity and liabilities10/49€1.18M€2.76M▲
Equity10/15€692k€832k▲
Contributions10/11€6k€6k=
Reserves13€2k€2k=
Non-distributable reserves130/1€2k-
Reserves not available under the articles1311€2k-
Distributable reserves133-€2k
Profit (loss) carried forward14€684k€824k▲
Amounts payable17/49€486k€1.93M▲
Amounts payable after more than one year17€165k€1.28M▲
Financial debts170/4€165k€1.28M▲
Amounts payable within one year42/48€320k€639k▲
Current portion of amounts payable after more than one year42€16k€104k▲
Trade debts44€205k€438k▲
Suppliers440/4€205k€438k▲
Taxes, remuneration and social security45€37k€53k▲
Taxes450/3€15k€18k▲
Remuneration and social security454/9€21k€35k▲
Other amounts payable47/48€63k€44k▼
Accrued charges and deferred income492/3€230€3k▲
Income statement
Code20232024
Remuneration, social security and pensions62€167k€211k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€16k€43k▲
Other operating charges640/8€2k€3k▲
Non-recurring operating charges66A-€100
Gross operating margin9900€424k€473k▲
Operating profit (loss)9901€240k€217k▼
Financial income75/76B€319€3k▲
Recurring financial income75€319€3k▲
Financial charges65/66B€4k€17k▲
Recurring financial charges65€4k€17k▲
Profit (loss) for the period before taxes9903€235k€203k▼
Income taxes67/77€45k€22k▼
Profit (loss) for the period9904€190k€180k▼
Profit (loss) for the period to be appropriated9905€190k€180k▼
Appropriation of the result
Profit (loss) to be appropriated9906€744k€864k▲
Profit (loss) brought forward from the previous period14P€554k€684k▲
Profit to be distributed694/7€60k€40k▼
Directors or managers695€60k€40k▼
Social balance
Average headcount (FTE)90873.33.4▲
The notes to these accounts (22 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
23-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
04-07
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial
Highest result since 2018net €190k ▲12.1%
Operating result €240k, net result €190k, both a record.
26-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
31-12
Financial
Equity above €500kEq €562k ▲22.8%
5 profitable years in a row build equity to €562k.
15-07
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
09-07
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
16-07
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
31-12
Financial
Weakest financial yearnet €120k ▼22.8%
Net result drops to €120k, the lowest in the series; recovery starts the following year.
18-06
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
21-06
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
07-07
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
2016
30-07
NBB filing
Annual accounts filed
fiscal year 2015 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Paliseul · 1 establishment unit since 2005
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Grand-Place 166850 PaliseulGround area
362 m²
Building footprint
185 m²
Volume, LiDAR
1,734 m³
Parcel 84050A0135/00F000, Wallonia · tallest building 11.9 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
PHARMACIE VANHEMMENS
since 20052.148.082.321
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 84050A0135/00F000 | Wallonia | 362 m² | 1 · 185 m² | 11.9 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHARMACIE ERGO
BE 0869.621.727
Estinnes · Eq €832,717
Apotheek De Kerselaar Harelbeke
BE 0863.507.658
Harelbeke · Eq €832,033
ASSENTFARMA
BE 0476.449.350
Bekkevoort · Eq €831,368
APOTHEEK POLLET LORENZ
BE 0723.875.267
Deinze · Eq €833,693
Pharmacie Van Gelder
BE 0847.201.661
Colfontaine · Eq €831,049
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,138 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded07-07-2005
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 19 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.